We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Evaluation of in vitro fertilization outcomes using interleukin-8 in culture medium of human preimplantation embryos.
Fertility and Sterility 2017 March
OBJECTIVE: To investigate whether selected cytokines are detectable in the embryo culture medium (EM) of human preimplantation embryos (HPE) and what the relationship is of the cytokines with clinical outcomes.
DESIGN: Cross-sectional study.
SETTING: University-affiliated tertiary teaching hospital.
PATIENT(S): Three-hundred and thirty infertile women who underwent fresh cycle in vitro fertilization (IVF) between January and December 2014.
INTERVENTION(S): Collection on the day of transfer of the EM of each embryo that was transferred in all patients for measurement of cytokine levels.
MAIN OUTCOME MEASURE(S): Measurement of 13 selected cytokines in the EM of day-3 HPE to analyze the relationship of the cytokine with embryo quality and clinical outcome.
RESULT(S): Of the cytokines measured, only interleukin-8 (IL-8) was statistically significantly associated with clinical outcome. The rate of detectable IL-8 in the EM was 32.42%, and the pregnancy rate, implantation rate, and number of live births per in vitro fertilization (IVF) or intracytoplasmic sperm injection patient (N LBPP) were higher, and 0 IR was lower in patients for whom the medium from transferred embryos was positive for IL-8 (IL-8 positive group) compared with the patients for whom the medium tested negative for IL-8 (IL-8 negative group). Compared with the IL-8 negative group, a higher pregnancy rate was observed in the IL-8 positive group when the patients received equal good-ordinary quality embryos.
CONCLUSION(S): In the EM from HPE, IL-8 is associated with higher pregnancy rates, higher IRs, and higher N LBPP, so IL-8 may be an independent predictor for pretransfer assessment of the embryo development potential in IVF patients.
DESIGN: Cross-sectional study.
SETTING: University-affiliated tertiary teaching hospital.
PATIENT(S): Three-hundred and thirty infertile women who underwent fresh cycle in vitro fertilization (IVF) between January and December 2014.
INTERVENTION(S): Collection on the day of transfer of the EM of each embryo that was transferred in all patients for measurement of cytokine levels.
MAIN OUTCOME MEASURE(S): Measurement of 13 selected cytokines in the EM of day-3 HPE to analyze the relationship of the cytokine with embryo quality and clinical outcome.
RESULT(S): Of the cytokines measured, only interleukin-8 (IL-8) was statistically significantly associated with clinical outcome. The rate of detectable IL-8 in the EM was 32.42%, and the pregnancy rate, implantation rate, and number of live births per in vitro fertilization (IVF) or intracytoplasmic sperm injection patient (N LBPP) were higher, and 0 IR was lower in patients for whom the medium from transferred embryos was positive for IL-8 (IL-8 positive group) compared with the patients for whom the medium tested negative for IL-8 (IL-8 negative group). Compared with the IL-8 negative group, a higher pregnancy rate was observed in the IL-8 positive group when the patients received equal good-ordinary quality embryos.
CONCLUSION(S): In the EM from HPE, IL-8 is associated with higher pregnancy rates, higher IRs, and higher N LBPP, so IL-8 may be an independent predictor for pretransfer assessment of the embryo development potential in IVF patients.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app